Recent Publications View all

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE To estimate 10-year overall survival (OS) rates for patients with early-onset breast cancer, with and without a BRCA1 mutation, and to identify prognostic factors among those with BRCA1-positive breast cancer. PATIENTS AND METHODSA total of 3,345 women with stage I to III breast cancer, age ≤ 50 years, were tested for three founder mutations in BRCA1. Information on tumor characteristics and treatments received was retrieved from medical records. Dates of death were obtained from the vital statistics registry. Survival curves for the mutation-positive and -negative subcohorts were compared. Predictors of OS were determined using the Cox proportional hazards model. RESULTS Of the 3,345 patients enrolled onto the study, 233 (7.0%) carried a BRCA1 mutation. The 10-year survival rate for mutation carriers was 80.9% (95% CI, 75.4% to 86.4%); for noncarriers, it was 82.2% (95% CI, 80.5% to 83.7%). The adjusted hazard ratio (HR) associated with carrying a BRCA1 mutation was 1.81 (95% CI, 1.26 to 2.61). Among BRCA1 carriers with a small (< 2 cm) node-negative tumor, the 10-year survival rate was 89.9%. Among BRCA1 mutation carriers, positive lymph node status was a strong predictor of mortality (adjusted HR, 4.1; 95% CI, 1.8 to 8.9). Oophorectomy was associated with improved survival in BRCA1 carriers (adjusted HR, 0.30; 95% CI, 0.12 to 0.75). CONCLUSION The 10-year survival rate among women with breast cancer and a BRCA1 mutation is similar to that of patients without a BRCA1 mutation. Among women with a BRCA1 mutation, survival was much improved after oophorectomy.
    Journal of Clinical Oncology 08/2013; 31(26). DOI:10.1200/JCO.2012.45.3571
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aims: Evaluation of FDG-PET usefulness in diagnosis and qualification for surgical treatment of advanced gastric cancer. Material and methods: Sixteen advanc ed gastric cancer patients (T2,N0-3,M0-1) who underwent FDG-PET/CT imaging and surgical treatment were evaluated retrospectively. Detailed data influencing cancer detection such as primary tumour size, depth of invasion, histological and Lauren classification type as well as tumour location were analysed. Correspondence between FDG-PET/CT and postoperative histo pathological evaluation of nodal involvement was assessed. Results: 60% of tumours larger than 4 cm, 75% of pT2 and pT3 tumours, 60% of mucocellular type and 75% of poorly or undifferentiated type tumours, and 77% of non-intestinal Lauren type tumours were detected. No tumour smaller than 4 cm was identified. 75% of tumours located in the middle one-third of the stomach were not detected. Also no resectable gastric cancer patient with nodal involvement was N(+) with FDG-PET/CT. Conclusions: 1. Primary tumour size and location may influence FDG-PET/CT results. 2. FDG-PET/CT is not a sufficient method of detection of all histological types of gastric cancer. 3. FDG-PET/CT is not a sufficient method of preoperative assessment of perigastric lymph nodes; thus this examination does not enable proper qualification for radical operative treatment in advanced gastric cancer (T2-4,N0-3,M0-1). 5. Detection of increased FDG uptake in perigastric lymph nodes may support unresectability of gastric cancer.
    Contemporary Oncology / Wspólczesna Onkologia 04/2013; 17(2):165-170. DOI:10.5114/wo.2013.34621
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background and Objective The rapid development of molecular biology techniques allows for the introduction of real-time polymerase chain reaction (PCR) methods with a limit of mutation detection at 1 % in a background of wild-type DNA. Analysis of KRAS mutations in codons 12, 13, and 61, together with analysis of BRAF mutations in codon 600, are predictive biomarkers for anti-epidermal growth factor receptor (EGFR) treatment in colorectal cancer. Our aim was to compare PCR methods for KRAS mutations and BRAF mutation analysis using DNA isolated from tissue samples previously evaluated for presence of tumor cells using a quantitative scale and the percentage of tumor cells (PTC) scale. We addressed the question of whether a low number of tumor cells can be qualified for somatic mutation testing. Results Our study showed that PTC as low as 10 % was good enough to detect KRAS G12D, G13D, and Q61L mutations in formalin-fixed paraffin-embedded (FFPE) material. Furthermore, our results indicate that up to 20 % of colorectal cancer may carry mutations in the KRAS codon 61 and BRAF codon 600, which suggests the value of these mutation analyses because patients carrying them are unlikely to respond to cetuximab or panitumumab. A low level of KRAS somatic mutation detection has not been studied in depth in the context of clinical outcomes in patients; therefore, we compared new PCR methods, (KRBR-RT 50 Entrogen; ViennaLab StripAssay) and re-evaluated KRAS and BRAF status in patients with relapse after targeted therapy. Conclusions The importance of molecular results was confirmed by clinical observation of a patient with relapse who had qualified for targeted therapy with KRAS WT status (but was diagnosed by less sensitive single-stranded conformation polymorphisms method). Interestingly, during anti-EGFR treatment, it came to the selection of cells with KRAS G12C mutation which were present from the beginning in the tumor but at a low level (detected by PCR methods) only and led consequently to the metastasis. Taking into consideration the limit of detection, labor time, and assay cost, the real-time PCR method seems to be very promising especially for FFPE material with the PTC below 15 %.
    Molecular Diagnosis & Therapy 04/2013; 17(3). DOI:10.1007/s40291-013-0025-8


  • Address
    Romanowskiej 2, 85 796, Bydgoszcz, Poland
  • Phone
Information provided on this web page is aggregated encyclopedic and bibliographical information relating to the named institution. Information provided is not approved by the institution itself. The institution’s logo (and/or other graphical identification, such as a coat of arms) is used only to identify the institution in a nominal way. Under certain jurisdictions it may be property of the institution.

19 Members View all

View all

Top publications last week by reads

Reports of Practical Oncology and Radiotherapy 12/2006; 11(5):217-222. DOI:10.1016/S1507-1367(06)71066-5
4 Reads
Acta haematologica Polonica 07/2013; 44(3):314–318. DOI:10.1016/j.achaem.2013.07.013
4 Reads

Top Collaborating Institutions


This map visualizes which other institutions researchers from Centrum Onkologii w Bydgoszczy have collaborated with.

Rg score distribution

See how the RG Scores of researchers from Centrum Onkologii w Bydgoszczy are distributed.